Hence, Alisol B 23-acetate is anticipated to show pharmacological effects similar to FXR agonists such as obeticholic acid and ursodeoxycholic acid in NAFLD treatment. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.